[18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease (Q43597594)

25 November 2017

[18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease (English)

1 reference

25 November 2017

0 references

Shizuo Hatashita

1

1 reference

25 November 2017

Hidetomo Yamasaki

2

1 reference

25 November 2017

Yutaka Suzuki

3

1 reference

25 November 2017

Kumiko Tanaka

4

1 reference

25 November 2017

Daichi Wakebe

5

1 reference

25 November 2017

Hideki Hayakawa

6

1 reference

25 November 2017

2 October 2013

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

25 November 2017

11

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

25 November 2017

41

1 reference

25 November 2017

2

1 reference

25 November 2017

290-300

1 reference

https://scigraph.springernature.com/pub.10.1007/s00259-013-2564-y

25 November 2017

0 references

cites work

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2564-Y

Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2564-Y

Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2564-Y

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2564-Y

Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2564-Y

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2564-Y

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2564-Y

Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2564-Y

Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2564-Y

Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2564-Y

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2564-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2564-Y

The Clinical Dementia Rating (CDR): current version and scoring rules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2564-Y

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2564-Y

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2564-Y

Neuropathology of older persons without cognitive impairment from two community-based studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2564-Y

Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2564-Y

Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2564-Y

Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2564-Y

Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2564-Y

Clinicopathologic correlates in Alzheimer disease: assessment of clinical and pathologic diagnostic criteria.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24085503

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24085503

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00259-013-2564-Y

1 reference

25 November 2017

1 reference